Why the study?
Do platelets from patients with diabetes mellitus exhibit increased synthesis of prostaglandin-E-like material and aggregation compared to controls?
Do platelets from patients with diabetes mellitus exhibit increased synthesis of prostaglandin-E-like material and aggregation compared to controls?
Platelets from diabetic patients show increased prostaglandin synthetase activity, which may contribute to the heightened platelet aggregation and thrombotic risk associated with diabetes.
Answers are grounded in this paper and cite their sources.
May heighten thrombotic risk in diabetes; leaves open whether prostaglandin inhibition improves outcomes.
We studied the effects of ADP, epinephrine, collagen and arachidonic acid on platelet production of immunoreactive prostaglandin-E-like material and aggregation in 17 subjects with diabetes mellitus and 21 matched controls. Plateletrich plasma obtained from patients synthesized significantly (P less than 0.05) greater quantities of the prostaglandin-E-like material after exposure to 1 muM ADP, 1, 2 and 5 muM epinephrine and 1 microgram per milliliter of collagen than platelet-rich plasma obtained from controls. That obtained from the diabetic patients was significantly more sensitive (P less than 0.001) to the aggregating effects of the prostaglandin precursor, arachidonic acid, in vitro as compared to controls. Diabetic platelet-rich plasma metabolized arachidonic acid (0.5 mM) to immunoreactive prostaglandin-E-like material at a significantly greater rate (P less than 0.05) and extent (P less than 0.001) than that of controls. Thus, platelets obtained from diabetic patients possess increased activity of the prostaglandin synthetase system, and this characteristic may be related to the increased platelet aggregation associated with the disease.
No takes yet. Share an insight, caveat, or question.
Halushka et al. (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: